NEWS Release

Recent Market Activity

Date: April 12, 2004

Toronto Stock Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

At the request of the Toronto Stock Exchange the Company has been asked to comment on the recent drop in the share price. All corporate developments have been announced and the Company is not aware of anything to cause the drop in the share price.

The Company has been cleared to begin a Pivotal Phase IIb/III trial for Tectin™ in moderate to severe inadequately controlled cancer related pain. The trial is expected to start shortly as the process of obtaining Ethics Committee approvals advances. This trial could be the last study before receiving market authorization.

International Wex Technologies Inc., a publicly listed neuro-bioscience company (WXI), is focused on the development and commercialization of innovative drug products, primarily for pain management. The Company's lead compound, Tetrodotoxin, is a sodium channel blocker and is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.

For additional information on our products visit us at http://www.wextech.ca or call Gordon Stanley, Corporate Communications at 604-683-8880, or at 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.